Table 2.

Tumor responses as assessed by investigator using RECIST v1.1.

Parameter	Total patients (N = 31)a	PD-L1 CPS <5 (n = 20)	PD-L1 CPS ≥5 (n = 9)
BOR, n (%)
CR	0	0	0
PR	8 (25.8)	5 (25.0)	2 (22.2)
SD	14 (45.2)	7 (35.0)	6 (66.7)
PD	8 (25.8)	7 (35.0)	1 (11.1)
Unknown/not evaluable	1 (3.2)	1 (5.0)	0
ORRb, n (%)	8 (25.8)	5 (25.0)	2 (22.2)
95% CIc	11.9–44.6	8.7–49.1	2.8–60.0
DCRd, n (%)	22 (71.0)	12 (60.0)	8 (88.9)
95% CIc	52.0–85.8	36.1–80.9	51.8–99.7

Note: BOR of CR or PR required confirmation by a subsequent assessment of response at least 28 days later. SD must have occurred ≥5 weeks following the first dose of the study drug to be considered the BOR.

^aCPS was not available for two patients.

^bORR = CR+PR.

^cCI was calculated using the Clopper–Pearson exact method.

^dDCR = CR+PR+SD.